{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:28:00Z","timestamp":1768969680740,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Faculty of Medicine, Ramathibodi hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12882-017-0573-y","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T07:48:00Z","timestamp":1494575280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review"],"prefix":"10.1186","volume":"18","author":[{"given":"Songkiat","family":"Chantarogh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soamarat","family":"Vilaiyuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thipwimol","family":"Tim-Aroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchin","family":"Worawichawong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"issue":"5","key":"573_CR1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.semarthrit.2008.09.001","volume":"39","author":"T Pettersson","year":"2010","unstructured":"Pettersson T, Konttinen YT. Amyloidosis-recent developments. Semin Arthritis Rheum. 2010;39(5):356\u201368.","journal-title":"Semin Arthritis Rheum"},{"issue":"3\u20134","key":"573_CR2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/13506129.2010.526812","volume":"17","author":"JD Sipe","year":"2010","unstructured":"Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the international society of Amyloidosis. Amyloid. 2010;17(3\u20134):101\u20134.","journal-title":"Amyloid"},{"issue":"6","key":"573_CR3","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/ndt\/gfm041","volume":"22","author":"F Bergesio","year":"2007","unstructured":"Bergesio F, Ciciani AM, Santostefano M, Brugnano R, Manganaro M, Palladini G, et al. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis. Nephrol Dial Transplant. 2007;22(6):1608\u201318.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"573_CR4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/93.8.535","volume":"93","author":"N Joss","year":"2000","unstructured":"Joss N, McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000;93(8):535\u201342.","journal-title":"QJM"},{"issue":"10","key":"573_CR5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrneph.2013.171","volume":"9","author":"JD Gillmore","year":"2013","unstructured":"Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol. 2013;9(10):574\u201386.","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"573_CR6","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361\u201371.","journal-title":"N Engl J Med"},{"issue":"1","key":"573_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/rheumatology\/ken409","volume":"48","author":"NA Ayaz","year":"2009","unstructured":"Ayaz NA, Ozen S, Bilginer Y, Erguven M, Taskiran E, Yilmaz E, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2009;48(1):23\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"573_CR8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00296-009-1331-7","volume":"32","author":"L Cantarini","year":"2012","unstructured":"Cantarini L, Lucherini OM, Simonini G, Galeazzi M, Baldari CT, Cimaz R. Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene. Rheumatol Int. 2012;32(2):465\u20137.","journal-title":"Rheumatol Int"},{"issue":"5","key":"573_CR9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40291-014-0105-4","volume":"18","author":"HM Lotfy","year":"2014","unstructured":"Lotfy HM, Kandil ME, Issac MS, Salah S, Ismail NA, Abdel Mawla MA. MEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritis. Mol Diagn Ther. 2014;18(5):549\u201357.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"573_CR10","first-page":"85","volume":"11","author":"J David","year":"1993","unstructured":"David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol. 1993;11(1):85\u201390.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"573_CR11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford). 2002;41(12):1428\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"573_CR12","first-page":"907","volume":"35","author":"K Immonen","year":"2008","unstructured":"Immonen K, Savolainen A, Kautiainen H, Hakala M. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis. J Rheumatol. 2008;35(5):907\u201312.","journal-title":"J Rheumatol"},{"issue":"6","key":"573_CR13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00296-005-0074-3","volume":"26","author":"F Onen","year":"2006","unstructured":"Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26(6):489\u201396.","journal-title":"Rheumatol Int"},{"issue":"6","key":"573_CR14","first-page":"1091","volume":"26","author":"K Migita","year":"2008","unstructured":"Migita K, Nakamura T, Maeda Y, Miyashita T, Koga T, Tanaka M, et al. MEFV mutations in Japanese rheumatoid arthritis patients. Clin Exp Rheumatol. 2008;26(6):1091\u20134.","journal-title":"Clin Exp Rheumatol"},{"issue":"5 Suppl 42","key":"573_CR15","first-page":"S51","volume":"24","author":"AY Hershko","year":"2006","unstructured":"Hershko AY, Ben-Chetrit E. The MEFV E148Q allele: a deleterious mutation or harmless variation? Clin Exp Rheumatol. 2006;24(5 Suppl 42):S51\u20132.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"573_CR16","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.3899\/jrheum.090250","volume":"36","author":"D Marek-Yagel","year":"2009","unstructured":"Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y. Is E148Q a benign polymorphism or a disease-causing mutation? J Rheumatol. 2009;36(10):2372.","journal-title":"J Rheumatol"},{"issue":"3","key":"573_CR17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1523-1755.2005.00535.x","volume":"68","author":"LM Dember","year":"2005","unstructured":"Dember LM. Emerging treatment approaches for the systemic amyloidoses. Kidney Int. 2005;68(3):1377\u201390.","journal-title":"Kidney Int"},{"issue":"4","key":"573_CR18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s10067-005-0048-6","volume":"25","author":"C Duarte","year":"2006","unstructured":"Duarte C, Gomes C, Correia AJ, Salgado M. Renal amyloidosis: an uncommon complication of juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(4):548\u20139.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"573_CR19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1053\/j.ajkd.2013.02.377","volume":"62","author":"A Saha","year":"2013","unstructured":"Saha A, Chopra Y, Theis JD, Vrana JA, Sethi S. AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis. 2013;62(4):834\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"573_CR20","first-page":"1111","volume":"29","author":"AD Billiau","year":"2002","unstructured":"Billiau AD, Cornillie F, Wouters C. Infliximab for systemic onset juvenile idiopathic arthritis: experience in 3 children. J Rheumatol. 2002;29(5):1111\u20134.","journal-title":"J Rheumatol"},{"issue":"5","key":"573_CR21","first-page":"935","volume":"32","author":"Y Kimura","year":"2005","unstructured":"Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2005;32(5):935\u201342.","journal-title":"J Rheumatol"},{"issue":"5","key":"573_CR22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.090952","volume":"36","author":"RA Russo","year":"2009","unstructured":"Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36(5):1078\u201382.","journal-title":"J Rheumatol"},{"issue":"5","key":"573_CR23","first-page":"723","volume":"20","author":"RA Russo","year":"2002","unstructured":"Russo RA, Katsicas MM, Zelazko M. Etanercept in systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20(5):723\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"573_CR24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.amjmed.2009.11.010","volume":"123","author":"A Fernandez-Nebro","year":"2010","unstructured":"Fernandez-Nebro A, Olive A, Castro MC, Varela AH, Riera E, Irigoyen MV, et al. Long-term TNF-alpha blockade in patients with amyloid a amyloidosis complicating rheumatic diseases. Am J Med. 2010;123(5):454\u201361.","journal-title":"Am J Med"},{"issue":"7","key":"573_CR25","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/art.11163","volume":"48","author":"JE Gottenberg","year":"2003","unstructured":"Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum. 2003;48(7):2019\u201324.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"573_CR26","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"9617","key":"573_CR27","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","volume":"371","author":"S Yokota","year":"2008","unstructured":"Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998\u20131006.","journal-title":"Lancet"},{"issue":"2","key":"573_CR28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","volume":"22","author":"A Courties","year":"2015","unstructured":"Courties A, Grateau G, Philippe P, Flipo RM, Astudillo L, Aubry-Rozier B, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid. 2015;22(2):84\u201392.","journal-title":"Amyloid"},{"issue":"1","key":"573_CR29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2013.854048","volume":"24","author":"Y Okuda","year":"2014","unstructured":"Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137\u201343.","journal-title":"Mod Rheumatol"},{"issue":"9","key":"573_CR30","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/art.22118","volume":"54","author":"Y Okuda","year":"2006","unstructured":"Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid a amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006;54(9):2997\u20133000.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"573_CR31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jbspin.2008.08.007","volume":"76","author":"B Nowak","year":"2009","unstructured":"Nowak B, Jeka S, Wiland P, Szechinski J. Rapid and complete resolution of ascites and hydrothorax due to nephrotic syndrome caused by renal amyloidosis in a patient with juvenile chronic arthritis treated with adalimumab. Joint Bone Spine. 2009;76(2):217\u20139.","journal-title":"Joint Bone Spine"},{"issue":"3","key":"573_CR32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/annrheumdis-2012-202156","volume":"72","author":"M Hakala","year":"2013","unstructured":"Hakala M, Immonen K, Korpela M, Vasala M, Kauppi MJ. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-alpha therapy resistant reactive amyloidosis. Ann Rheum Dis. 2013;72(3):464\u20135.","journal-title":"Ann Rheum Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-017-0573-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T07:48:10Z","timestamp":1494575290000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-017-0573-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/s12882-017-0573-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"article-number":"159"}}